Winter 2024

Protein Engineering & Services

Engineered biological antibodies such as bispecific antibodies, ADCs, radiopharmaceuticals, antibody fragments, synthetic peptide-hormone combinations or chimeric antigen receptors are currently transforming medicine due to their superior target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity profiles.

Last year, these biologics accounted for 48% of FDA approvals. European Biotechnology will report on the latest advances in AI-driven antibody design, analytical characterisation, formulation, targeting and delivery, process development and related services (i.e. preclinical drug development) from the best biologics technology meeting in 2024: the PEGS Europe in Barcelona. Gain visibility in this interesting editorial environment and present your offer/portfolio to customers.

Topics to be covered
Protein Engineering/Conjugates/ Services: Antibody conjugation, multispecifics engineering, CAR-engineering and expression, analytical testing, formulation and optimisation, pre/clinical development, QS, process development, automation, manufacturing, challenges with ADCs, radio-conjugates, delivery strategies, TME targeting, equipment, automated screening, glyco-engineering, stratification, drug discovery services, immunooncology, biomarker/drug approval, animal/organoid models, AI tools, your platform, and more.

Contact:
Editorial Contact: Thomas Gabrielczyk (t.gabrielczyk@biocom.de)
Marketing Contact: Oliver Schnell (o.schnell@biocom.de), Andreas Macht (a.macht@biocom.de)